Table 1.
Comparison of general characteristics of the study population according to having been treated with TCZ.
| Population without TCZ [n = 159] | TCZ subpopulation [n = 77] | p | |
|---|---|---|---|
| Demographics | |||
| Age (median), years | 57.0 (44.0–70.0) | 62.0 (53.0–72.0) | .061 |
| Males, % | 57.2 (91/159) | 64.9 (50/77) | .258 |
| Nosocomial, % | 3.8 (6/159) | 2.6 (2/76) | .652 |
| Long-term care resident, % | 0.6 (1/159) | 0.0 (0/77) | .486 |
| Health professional, % | 11.9 (19/159) | 11.7 (9/77) | .954 |
| Comorbidities | |||
| Hypertension, % | 40.3 (64/159) | 41.6 (32/77) | .848 |
| Diabetes, % | 16.4 (26/159) | 20.8 (16/77) | .552 |
| Body mass index, kg/m2 | 27.6 (24.2–31.6) | 28.1 (25.0–32.2) | .348 |
| Obesity, % | 35.5 (54/152) | 34.7 (26/75) | .899 |
| Cardiovascular disease, % | 8.2 (13/159) | 7.8 (6/77) | .779 |
| Chronic respiratory disease, % | 16.5 (26/159) | 14.3 (11/77) | .736 |
| Immunosuppression, % | 10.1 (16/159) | 5.2 (4/77) | .203 |
| Charlson comorbidity index | 2 (0–4) | 2.0 (1.0–3.0) | .662 |
| Charlson index ≥3, % | 38.4 (61/159) | 42.9 (33/77) | .509 |
| 10-years expected survivala | 90.2 (53.4–98.3) | 90.0 (74.0–95.9) | .264 |
| Clinical Presentation | |||
| Clinical duration, daysb | 7.0 (3.0–9.0) | 7.0 (4.0–10.0) | .442 |
| Fever, % | 73.6 (117/159) | 90.9 (70/77) | .002 |
| Dry cough, % | 64.8 (103/159) | 68.4 (52/76) | .582 |
| Wet cough, % | 15.7 (25/159) | 20.8 (16/77) | .336 |
| Dyspnea, % | 44.3 (70/158) | 64.5 (49/76) | .004 |
| Diarrhoea, % | 25.6 (40/156) | 35.1 (27/77) | .135 |
| Confusion, % | 6.4 (10/156) | 6.6 (5/76) | 1.000 |
| Fatigue, % | 41.7 (63/151) | 54.7 (41/75) | .066 |
| Myalgias-arthralgias, % | 33.1 (51/154) | 32.0 (24/75) | .866 |
| Anosmia-dysgeusia, % | 15.1 (23/152) | 13.5 (10/74) | .746 |
| Initial Assessment | |||
| Oximetry at room air (%) | 96.0 (94.0–98.0) | 93.0 (89.0–95.3) | .000 |
| PaO2:FiO2, mm Hg | 361.9 (310.0–442.0) | 307.0 (269.8–341.3) | .000 |
| Respiratory rate, breaths/min | 16.0 (16.0–18.0) | 24.0 (17.0–32.0) | .000 |
| Systolic BP, mmHg | 132.0 (116.0–145.0) | 127.0 (111.0–144.0) | .509 |
| Diastolic BP, mmHg | 82.0 (73.0–91.0) | 74.0 (67.0–84.5) | .002 |
| Heart rate, beats/min | 96.0 (83.0–106.0) | 95.0 (87.0–107.0) | .959 |
| CURB65 | 0.0 (0.0–1.0) | 1.0 (0.0–2.0) | .004 |
| eGFR, ml/min/m2 | 89.4 (70.0–90.0) | 83.4 (68.9–90.0) | .326 |
| eGFR <60 ml/min/m2, % | 18.2 (29/159) | 14.7 (11/75) | .498 |
| Leukocytes, per mm3 | 6410.0 (5065.0–8402.5) | 6000.0 (4920.0–8290.0) | .445 |
| Lymphocytes, per mm3 | 1200.0 (860.0–1510.0) | 860.0 (625.0–1055.0) | .000 |
| C-reactive protein, mg/dL | 4.0 (1.7–8.5) | 11.0 (5.8–17.2) | .000 |
| Procalcitonin, ng/mL | 0.1 (0.1–0.2) | 0.1 (0.1–0.3) | .000 |
| Ferritin, mg/L | 551.0 (281.5–978.0) | 1220.5 (532.3–2263.0) | .000 |
| Lactate dehydrogenase, U/L | 241.0 (202.0–317.0) | 349.0 (275.8–441.0) | .000 |
| D-dimers, mg/mL | 0.6 (0.4–0.9) | 0.8 (0.5–1.2) | .008 |
| Interleukin 6, pg/mL | 18.0 (8.0–34.0) | 66.5 (31.3–158.0) | .000 |
| Troponin T, ng/L | 7.0 (5.0–14.3) | 10.0 (6.0–17.0) | .022 |
| Brain natriuretic peptide, pg/mL | 64.0 (23.0–191.0) | 104.0 (33.0–320.5) | .161 |
| Creatine phosphokinase, U/L | 79.0 (51.5–137.5) | 97.0 (64.0–152.5) | .064 |
| Aspartate aminotransferase, U/L | 30.0 (22.0–44.5) | 43.5 (29.5–76.3) | .000 |
| Alanine aminotransferase, U/L | 26.0 (16.0–43.0) | 34.5 (19.5–55.0) | .009 |
| Opacities >50% of lung surface on X-rays, % | 8.2 (13/159) | 34.2 (26/76) | <0.001 |
Data shown as % unless specified otherwise. In bold, statistically significant differences.
a
10-years expected survival derived from Charlson comorbidity index score.
b
Days of symptoms before admission. OR: odds ratio, 95%CI: 95% confidence interval.